Half-year report · Q2
9776.TEDINET S100ULLX
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥19.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥338m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥291m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥343m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥515m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥296m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥344m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥386m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥222m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥380m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥226m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥16.4bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥16.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥16.7bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.5bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥11.2bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.4bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥407m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥810m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥584m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥395m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥171m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥398m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥370m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥238m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥70.87 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.94 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥37m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥158m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥352m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥800m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥426m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥507m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥545m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥41m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥78m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥377m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥798m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥492m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥489m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 543
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 77718000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 377021000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | -6650000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 448090000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 41400000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 489490000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3909865000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5607948000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 425517000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 9943332000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 53644000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 9996976000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 374945000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 374945000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4033000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 378979000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3909865000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5607948000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 800463000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 10318277000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 57678000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10375956000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 158067000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 351640000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | -2244000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 507463000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 37124000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 544587000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)北海道財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-11 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第61期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Company name in english cover page | FilingDateInstant | SAPPORO CLINICAL LABORATORY INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 伊達 忠應 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０１１（６１３）３２１０ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)総務部長 南 誠 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０１１（６１３）３２１０ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)総務部長 南 誠 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E04950 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 97760 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Filer name in english | FilingDateInstant | SAPPORO CLINICAL LABORATORY INC. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |